Patents Assigned to Galmed Research and Development Ltd.
-
Patent number: 11571431Abstract: The present invention relates to salts of arachidyl amido cholanoic acid (Aramchol), pharmaceutical compositions comprising Aramchol salts, methods for their preparation, and methods of use thereof in medical treatment.Type: GrantFiled: October 24, 2021Date of Patent: February 7, 2023Assignee: Galmed Research and Development LtdInventors: Allen Baharaff, Idit Eshkar-Oren
-
Patent number: 11197870Abstract: The invention relates to the treatment and reduction of fibrosis, specifically hepatic fibrosis. More specifically, embodiments of the invention provide compositions and methods useful for the treatment and inhibition of hepato-fibrotic conditions associated with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), employing the use of 3?-arachidylamido-7?,12?-dihydroxy-5?-cholan-24-oic acid (Aramchol) or a pharmaceutically acceptable salt thereof. In other embodiments, the treatment and inhibition of hepato-fibrotic conditions caused by contact with hepatotoxic chemical substances or by mechanical obstruction is contemplated.Type: GrantFiled: October 20, 2017Date of Patent: December 14, 2021Assignee: Galmed Research and Development LtdInventors: Liat Hayardeny-Nissimov, Tali Gorfine, Allen Baharaff, Jose M. Mato de la Paz
-
Patent number: 11166964Abstract: The present invention is directed to the modulation of gut microbiota. Specifically, the invention relates to pharmaceutical compositions for use in restoring gastrointestinal homeostasis and in alleviating gastrointestinal disorders and other conditions associated with imbalance of gut flora. More specifically, the invention relates to the use of compositions comprising a therapeutically effective amount of a fatty acid bile acid conjugate (FABAC).Type: GrantFiled: January 19, 2017Date of Patent: November 9, 2021Assignee: Galmed Research and Development LtdInventors: Maya Halpern, Allen Baharaff
-
Publication number: 20210169901Abstract: The present invention is directed to the modulation of gut microbiota. Specifically, the invention relates to pharmaceutical compositions for use in restoring gastrointestinal homeostasis and in alleviating gastrointestinal disorders and other conditions associated with imbalance of gut flora. More specifically, the invention relates to the use of compositions comprising a therapeutically effective amount of a fatty acid bile acid conjugate (FABAC).Type: ApplicationFiled: January 19, 2017Publication date: June 10, 2021Applicant: Galmed Research and Development Ltd.Inventors: Maya Halpern, Allen Baharaff
-
Patent number: 10849911Abstract: The present invention relates to salts of arachidyl amido cholanoic acid (Aramchol), pharmaceutical compositions comprising Aramchol salts, methods for their preparation, and methods of use thereof in medical treatment.Type: GrantFiled: June 8, 2016Date of Patent: December 1, 2020Assignee: Galmed Research and Development Ltd.Inventors: Allen Baharaff, Idit Eshkar-Oren
-
Publication number: 20190328751Abstract: The present invention relates to salts of arachidyl amido cholanoic acid (Aramchol), pharmaceutical compositions comprising Aramchol salts, methods for their preparation, and methods of use thereof in medical treatment.Type: ApplicationFiled: June 8, 2016Publication date: October 31, 2019Applicant: Galmed Research and Development Ltd.Inventors: Allen Baharaff, Idit Eshkar-Oren
-
Publication number: 20180125862Abstract: The invention relates to the treatment and reduction of fibrosis, specifically hepatic fibrosis. More specifically, embodiments of the invention provide compositions and methods useful for the treatment and inhibition of hepato-fibrotic conditions associated with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), employing the use of 3?-arachidylamido-7?,12?-dihydroxy-5?-cholan-24-oic acid (Aramchol) or a pharmaceutically acceptable salt thereof. In other embodiments, the treatment and inhibition of hepato-fibrotic conditions caused by contact with hepatotoxic chemical substances or by mechanical obstruction is contemplated.Type: ApplicationFiled: October 20, 2017Publication date: May 10, 2018Applicant: Galmed Research and Development Ltd.Inventors: Liat Hayardeny-Nissimov, Tali Gorfine, Allen Baharaff, Jose M. Mato de la Paz
-
Patent number: 8975246Abstract: A method for treating a disease or disorder associated with altered glucose metabolism or insulin action in a subject in need thereof. The method includes administering to the subject a BAFAC (bile acid or bile salt fatty acid conjugate) of general formula II: W-X-G in which G is a bile acid or bile salt radical, which is optionally conjugated in position 24 with a suitable amino acid, W stands for one or two fatty acid radicals, each having from 14-22 carbon atoms, and X is a suitable bonding member or a direct C?C bond between G and each W, said suitable bonding member being selected from the group consisting of NH, O, P and S. The disease or disorder associated with altered glucose metabolism is selected from the group consisting of hyperglycemia, diabetes, insulin resistance and obesity.Type: GrantFiled: February 6, 2012Date of Patent: March 10, 2015Assignee: Galmed Research and Development Ltd.Inventor: Beatrice Gilat